Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01610414
Registration number
NCT01610414
Ethics application status
Date submitted
31/05/2012
Date registered
4/06/2012
Date last updated
23/01/2018
Titles & IDs
Public title
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Query!
Scientific title
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Query!
Secondary ID [1]
0
0
2012-000138-20
Query!
Secondary ID [2]
0
0
115523
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Herpes Zoster
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Herpes Zoster vaccine GSK1437173A
Other interventions - Placebo
Experimental: GSK1437173A Group - Subjects received 2 doses of the candidate HZ vaccine GSK 1437173A, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
Placebo Comparator: Placebo Group - Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
Other interventions: Herpes Zoster vaccine GSK1437173A
2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
Other interventions: Placebo
2 doses administered IM in deltoid region of non-dominant arm
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Subjects With Confirmed Herpes Zoster (HZ) Episode
Query!
Assessment method [1]
0
0
A suspected case of HZ was defined as (1) a new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or a vesicular rash suggestive of VZV infection regardless of the distribution, and no alternative diagnosis; or (2) a clinical presentation (symptoms and/or signs) and specific laboratory findings* suggestive of VZV infection in the absence of characteristic HZ or VZV rash.
A suspected case of HZ was confirmed either: by Polymerase Chain Reaction (PCR) or by the HZ Ascertainment Committee (HZAC), consisting of physicians with HZ expertise.
Query!
Timepoint [1]
0
0
From Month 0 until the cut-off date for final analysis (median follow-up was of 21 months)
Query!
Secondary outcome [1]
0
0
Duration of 'Worst' HZ-associated Pain
Query!
Assessment method [1]
0
0
Duration of HZ-associated pain rated as 3 or greater on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) question, following the onset of a confirmed HZ rash over the entire pain reporting period in subjects with confirmed HZ; presented as T (day) [=the sum of follow-up period (for subjects without severe worst pain T is 1, for subjects with severe worst pain T is the duration of severe worst pain) expressed in days].
Query!
Timepoint [1]
0
0
From Month 0 until study end (4 years approximately), from the onset of a confirmed HZ rash over the entire pain reporting period
Query!
Secondary outcome [2]
0
0
Number of Subjects With Confirmed HZ-associated Complications
Query!
Assessment method [2]
0
0
This analysis excluded complications that were linked to a confirmed HZ case that occurred after the start of the relapse treatment.
Query!
Timepoint [2]
0
0
From Month 0 until the cut-off date for final analysis (median follow-up was of 21 months)
Query!
Secondary outcome [3]
0
0
Number of Subjects With Postherpetic Neuralgia (PHN)
Query!
Assessment method [3]
0
0
This analysis excluded PHN episodes that were linked to a confirmed HZ case that occurred after the start of the relapse treatment.
Query!
Timepoint [3]
0
0
From Month 0 until study end (21 months median follow-up)
Query!
Secondary outcome [4]
0
0
Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects
Query!
Assessment method [4]
0
0
Anti-gE antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (=) 97 mIU/mL.
Query!
Timepoint [4]
0
0
At Months 0, 1, 2, 13 and 25
Query!
Secondary outcome [5]
0
0
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Query!
Assessment method [5]
0
0
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Query!
Timepoint [5]
0
0
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Query!
Secondary outcome [6]
0
0
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Query!
Assessment method [6]
0
0
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary/tympanic temperature equal to or above 37.5 degrees Celsius (°C) or rectal temperature equal to or above 38.0 °C]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.
Query!
Timepoint [6]
0
0
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Query!
Secondary outcome [7]
0
0
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
Query!
Assessment method [7]
0
0
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Query!
Timepoint [7]
0
0
During the 30-day (Days 0-29) post-vaccination period
Query!
Secondary outcome [8]
0
0
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
Query!
Assessment method [8]
0
0
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Query!
Timepoint [8]
0
0
From Month 0 up to 365 days post last vaccination
Query!
Secondary outcome [9]
0
0
Number of Subjects With Any Relapse
Query!
Assessment method [9]
0
0
Relapse was defined as the occurrence of the underlying malignancy or disease for which the HCT was undertaken.
Query!
Timepoint [9]
0
0
From Month 0 until study end (approximate median of 29 months follow-up - minimum 1 year and maximum 4 years)
Query!
Secondary outcome [10]
0
0
Number of Subjects With Any Serious Adverse Events (SAEs) and Related SAEs to GSK Study Vaccine/Placebo
Query!
Assessment method [10]
0
0
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. This enpoint also presents SAES related to the GSK study vaccine/placebo.
Query!
Timepoint [10]
0
0
From Month 0 until 365 days post last vaccination (approximate median of 29 months follow-up - minimum 1 year and maximum 4 years)
Query!
Secondary outcome [11]
0
0
Number of Subjects With Fatal SAEs and SAEs Related to Study Participation or to a GSK Concomitant Medication or Vaccination
Query!
Assessment method [11]
0
0
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. This endpoint presents fatal SAEs and SAEs related to study participation or to a concurrent GSK medication/vaccine.
Query!
Timepoint [11]
0
0
From the Pre-vaccination visit (Up to 110 days prior Month 0) until study end (approximate median of 29 months follow-up minimum 1 year and maximum 4 years)
Query!
Eligibility
Key inclusion criteria
Study entry (enrollment) occurs at the Pre-vaccination visit.
- Subjects who the investigator believes can and will comply with the requirements of
the protocol.
- Written informed consent obtained from the subject.
- A male or female aged 18 years or older at the time of study entry.
- Has undergone or will undergo autologous HCT within 50-70 days prior to the first
vaccination with the study vaccine/placebo, and there are no plans for additional
HCTs.
- Female subjects of non-childbearing potential may be enrolled in the study. For this
study population, non-childbearing potential is defined as current tubal ligation,
hysterectomy, ovariectomy or post-menopause.
OR Female subjects of childbearing potential may be enrolled in the study, if the subject
has practiced adequate contraception for 30 days prior to vaccination with the study
vaccine/placebo, and has a negative pregnancy test on the day of vaccination, and has
agreed to continue adequate contraception during the entire treatment period and for 12
months after completion of the vaccination series (i.e., until Month 13).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Use of any investigational or non-registered product other than the study vaccine
within 30 days preceding the first dose of study vaccine/placebo, or planned use
during the study period. However, the investigational use of a registered or
non-registered product to treat the subject's underlying disease for which the HCT was
undertaken, or a complication of the underlying disease, is allowed.
- Previous vaccination against HZ or varicella within the 12 months preceding the first
dose of study vaccine/placebo.
- Planned administration during the study of a HZ vaccine other than the study vaccine.
- Occurrence of a varicella or HZ episode by clinical history within the 12 months
preceding the first dose of study vaccine/placebo.
- History of allergic disease or reactions likely to be exacerbated by any component of
the vaccine or study material and equipment.
- Prophylactic antiviral therapy with activity against Varicella Zoster Virus (VZV)
expected to last more than 6 months after transplantation.
- Administration and/or planned administration of a vaccine not foreseen by the study
protocol between HCT and 30 days after the last dose of study vaccine/placebo.
However, licensed non-replicating vaccines may be administered up to 8 days prior to
dose 1and/or 2, and/or at least 14 days after any dose of study vaccine/placebo.
- HIV infection by clinical history.
- Pregnant or lactating female.
- Female planning to become pregnant or planning to discontinue contraceptive
precautions (if of childbearing potential) before Month 13 (i.e., one year after the
last dose of study vaccine/placebo).
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/07/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1877
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,TAS,VIC
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Darlinghurst
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Waratah
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Westmead
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Woodville
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Hobart
Query!
Recruitment hospital [6]
0
0
GSK Investigational Site - Box Hill
Query!
Recruitment hospital [7]
0
0
GSK Investigational Site - East Melbourne
Query!
Recruitment hospital [8]
0
0
GSK Investigational Site - Heidelberg
Query!
Recruitment hospital [9]
0
0
GSK Investigational Site - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [5]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [6]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [7]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [8]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [9]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Kansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Kentucky
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Michigan
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Minnesota
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Jersey
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Washington
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Wisconsin
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Antwerpen
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Brugge
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Bruxelles
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Gent
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Hasselt
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Jette
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Leuven
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Liege
Query!
Country [24]
0
0
Bulgaria
Query!
State/province [24]
0
0
Sofia
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
British Columbia
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
New Brunswick
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Ontario
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Quebec
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Saskatchewan
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Hradec Kralove
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Olomouc
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Praha 10
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Praha 2
Query!
Country [34]
0
0
Estonia
Query!
State/province [34]
0
0
Tallinn
Query!
Country [35]
0
0
Finland
Query!
State/province [35]
0
0
Helsinki
Query!
Country [36]
0
0
Finland
Query!
State/province [36]
0
0
Tampere
Query!
Country [37]
0
0
Finland
Query!
State/province [37]
0
0
Turku
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Clermont-Ferrand Cedex 1
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Créteil cedex
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Grenoble cedex 9
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Marseille cedex 9
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Montpellier cedex 5
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Pessac cedex
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Rouen cedex 1
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Baden-Wuerttemberg
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Bayern
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Nordrhein-Westfalen
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Schleswig-Holstein
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Berlin
Query!
Country [50]
0
0
Greece
Query!
State/province [50]
0
0
Athens
Query!
Country [51]
0
0
Greece
Query!
State/province [51]
0
0
Thessaloniki
Query!
Country [52]
0
0
Hong Kong
Query!
State/province [52]
0
0
Hong Kong
Query!
Country [53]
0
0
Hong Kong
Query!
State/province [53]
0
0
Tuen Mun
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Hafia
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Jerusalem
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Emilia-Romagna
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Friuli-Venezia-Giulia
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Lombardia
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Piemonte
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Fukuoka
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Gunma
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Hiroshima
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Hyogo
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Kumamoto
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Nagasaki
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Niigata
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Okayama
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Shizuoka
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Tokyo
Query!
Country [70]
0
0
Korea, Republic of
Query!
State/province [70]
0
0
Daegu
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Incheon
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Jellanamdo
Query!
Country [73]
0
0
Korea, Republic of
Query!
State/province [73]
0
0
Jeonju
Query!
Country [74]
0
0
Korea, Republic of
Query!
State/province [74]
0
0
Kyunggi-do
Query!
Country [75]
0
0
Korea, Republic of
Query!
State/province [75]
0
0
Seoul
Query!
Country [76]
0
0
Malaysia
Query!
State/province [76]
0
0
Kuala Lumpur
Query!
Country [77]
0
0
Malaysia
Query!
State/province [77]
0
0
Selangor
Query!
Country [78]
0
0
Netherlands
Query!
State/province [78]
0
0
Leiden
Query!
Country [79]
0
0
New Zealand
Query!
State/province [79]
0
0
Christchurch
Query!
Country [80]
0
0
New Zealand
Query!
State/province [80]
0
0
Grafton
Query!
Country [81]
0
0
New Zealand
Query!
State/province [81]
0
0
Wellington
Query!
Country [82]
0
0
Panama
Query!
State/province [82]
0
0
Panama
Query!
Country [83]
0
0
Poland
Query!
State/province [83]
0
0
Gliwice
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Krakow
Query!
Country [85]
0
0
Poland
Query!
State/province [85]
0
0
Warszawa
Query!
Country [86]
0
0
Romania
Query!
State/province [86]
0
0
Bucharest
Query!
Country [87]
0
0
Romania
Query!
State/province [87]
0
0
Tirgu Mures
Query!
Country [88]
0
0
Russian Federation
Query!
State/province [88]
0
0
Moscow
Query!
Country [89]
0
0
Russian Federation
Query!
State/province [89]
0
0
Novosibirsk
Query!
Country [90]
0
0
Russian Federation
Query!
State/province [90]
0
0
Petrozavodsk
Query!
Country [91]
0
0
Russian Federation
Query!
State/province [91]
0
0
St'Petersburg
Query!
Country [92]
0
0
Russian Federation
Query!
State/province [92]
0
0
St.-Petersburg
Query!
Country [93]
0
0
Russian Federation
Query!
State/province [93]
0
0
St.Petersburg
Query!
Country [94]
0
0
South Africa
Query!
State/province [94]
0
0
Gauteng
Query!
Country [95]
0
0
South Africa
Query!
State/province [95]
0
0
Western Province
Query!
Country [96]
0
0
South Africa
Query!
State/province [96]
0
0
Groenkloof
Query!
Country [97]
0
0
South Africa
Query!
State/province [97]
0
0
Moreleta Park, Pretoria
Query!
Country [98]
0
0
Spain
Query!
State/province [98]
0
0
Badalona/Barcelona
Query!
Country [99]
0
0
Spain
Query!
State/province [99]
0
0
Barcelona
Query!
Country [100]
0
0
Spain
Query!
State/province [100]
0
0
La Coruña
Query!
Country [101]
0
0
Spain
Query!
State/province [101]
0
0
León
Query!
Country [102]
0
0
Spain
Query!
State/province [102]
0
0
Madrid
Query!
Country [103]
0
0
Spain
Query!
State/province [103]
0
0
Majadahonda (Madrid)
Query!
Country [104]
0
0
Spain
Query!
State/province [104]
0
0
Malaga
Query!
Country [105]
0
0
Spain
Query!
State/province [105]
0
0
Murcia (El Palmar)
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
Murcia
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Oviedo
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Pozuelo De Alarcón/Madrid
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
San Sebastián
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Santander
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Valencia
Query!
Country [112]
0
0
Taiwan
Query!
State/province [112]
0
0
Kaohsiung
Query!
Country [113]
0
0
Taiwan
Query!
State/province [113]
0
0
Taichung
Query!
Country [114]
0
0
Taiwan
Query!
State/province [114]
0
0
Taoyuan Hsien
Query!
Country [115]
0
0
Turkey
Query!
State/province [115]
0
0
Ankara
Query!
Country [116]
0
0
Turkey
Query!
State/province [116]
0
0
Istanbul
Query!
Country [117]
0
0
Turkey
Query!
State/province [117]
0
0
Izmir
Query!
Country [118]
0
0
United Kingdom
Query!
State/province [118]
0
0
Lanarkshire
Query!
Country [119]
0
0
United Kingdom
Query!
State/province [119]
0
0
Wiltshire
Query!
Country [120]
0
0
United Kingdom
Query!
State/province [120]
0
0
Bournemouth
Query!
Country [121]
0
0
United Kingdom
Query!
State/province [121]
0
0
Cottingham
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Headington, Oxford
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
Leeds
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the efficacy of GSK Biologicals' vaccine GSK1437173A
in the prevention of Herpes zoster (HZ) in autologous haematopoietic cell transplant
recipients 18 years of age and older. To this end, the study will evaluate vaccine efficacy
(VE) of the GSK1437173A vaccine, administered on a 2-dose schedule, compared to placebo in
reducing the risk of developing HZ in this population.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01610414
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01610414
Download to PDF